Early low-dose lenalidomide significantly reduces mutational burden without increasing AML risk in non-transfusion-dependent del(5q) MDS.

All rights reserved.) The European Commission (EC) has granted marketing authorisation for AbbVie’s Tepkinly (epcoritamab) in ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the ...

Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma (DLBLC), a positive phase 3 combination ...

AbbVie ABBV announced that the European Commission (EC) approved the expanded use of Tepkinly (epcoritamab) for the relapsed ...

Lenalidomide, a derivative of thalidomide, is a FDA-approved drug for the treatment of multiple myeloma (MM). Recent clinical studies have extended the therapeutic effectiveness of lenalidomide ...

The recommended starting dosage of lenalidomide for the treatment of MM is 25 mg/day p.o. on days 1-21 of a 28-day cycle. On the basis of the trials previously presented, the recommended dosage of ...

Extended lymphadenectomy and adjuvant chemotherapy in muscle-invasive bladder cancer treated by radical cystectomy. Background: Intravesical BCG is the gold standard for non-muscle-invasive bladder ...

Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire ...

Lenalidomide (Revlimid, Celgene) is an immunomodulating agent. It belongs to a class of agents often referred to as immunomodulatory derivatives, which are all structural derivatives of thalidomide.

Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) ...